Difference in prognostic value between sialyl Lewis(a) and sialyl Lewis(x) antigen levels in the preoperative serum of gastric cancer patients. 2002

Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
First Department of Surgery, Nagasaki University School of Medicine, Sasebo, Nagasaki, Japan. nakagoe@net.nagasaki-u.ac.jp

Sialyl Lewis(a) (CA19-9) and sialyl Lewis(x) antigens (SLX) may play a role in tumor metastasis by serving as functional ligands in the cell adhesion system. The authors examined preoperative serum levels of CA19-9 and SLX in 218 patients who underwent resection for gastric cancer to determine their prognostic value. The patients were divided into two groups, termed the low and high antigen groups, based on a value selected as a diagnostic cutoff. Correlation between the antigen serum levels, various established clinicopathologic factors, and prognosis were studied by univariate and multivariate analysis. The disease-specific interval for high CA19-9 and SLX groups was significantly shorter than that of their respective low groups (p = 0.0024 and p < 0.0001, respectively). Patients with stage III/IV tumors who had high serum SLX levels had shorter disease-specific intervals than those with low serum levels (p = 0.0017). A Cox's regression analysis revealed a high serum SLX level as an independent factor for worse outcome. In addition, logistic regression analysis revealed that a high serum SLX level was an independent predictor for liver metastasis. In conclusion, an elevated preoperative serum SLX level was a predictor for poor outcome after resection for gastric cancer, whereas CA19-9 was not.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009844 Oligosaccharides Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form. Oligosaccharide
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000080506 Sialyl Lewis X Antigen A sialylated version of Lewis X antigen expressed on cell surfaces. It is a ligand for SELECTINS. 5-Acetylneuraminyl-(2-3)-Galactosyl-(1-4)-(Fucopyranosyl-(1-3))-N-Acetylglucosamine,CD15s Antigen,Sialyl Le(x),Sialyl Lewis X,Sialyl Lewis(x) Antigen,Sialyl Lewis(x) Tetrasaccharide,Sialyl SSEA-1,Sialyl Stage-Specific Embryonic Antigen-1,Sialyl-Lex,Sialylated Lewis X Antigen,NAG-1,4-F-1,3-GN,Neu5Ac-2-3-Gal-1-4-(Fuc-1-3)-GlcNAc,NeuAcalpha2-3Galbeta1-4(Fucalpha1-3)GlcNAc-R,SLe(x),SLe(x)-OS,alpha-Neu5Ac-(2-3)-beta-D-Gal-(1-4)-(alpha-L-Fuc-(1-3))-beta-D-GlcNAc,Antigen, CD15s,Lewis X, Sialyl,Sialyl Lex,Sialyl SSEA 1,Sialyl Stage Specific Embryonic Antigen 1
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
January 1998, Anticancer research,
Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
September 1993, Cancer,
Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
January 1994, British journal of cancer,
Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
October 2008, International journal of surgical pathology,
Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
February 1996, Nihon Geka Gakkai zasshi,
Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
December 1989, Cancer,
Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
January 2002, Haematologia,
Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
May 2002, Histopathology,
Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
January 2021, Frontiers in immunology,
Tohru Nakagoe, and Terumitsu Sawai, and Takashi Tsuji, and Masa-aki Jibiki, and Atsushi Nanashima, and Hiroyuki Yamaguchi, and Toru Yasutake, and Hiroyoshi Ayabe, and Kokichi Arisawa, and Hiroshi Ishikawa
January 1994, International journal of oncology,
Copied contents to your clipboard!